Ten post jest także dostępny w języku: polski
The Polish network of clinical trials centres – Pratia, a member of the Neuca Group, has acquired a 40% stake in the German KFGN. It is a company operating on the clinical research centres market. Ultimately, Neuca will acquire 100% of shares.
KFGN: Over 700 clinical trials
KFGN has been operating on the clinical trials market for over 20 years. It has six centres in Hamburg, Hannover, Schwerin, Berlin, Dresden and Karslruhe. It specialises in insomnia research, medical devices and the entire spectrum of specialised research, including vaccination. To date, it has conducted about 700 clinical trials.
Neuca’s investment in KFGN has been divided into three stages. Ultimately, the Polish company will acquire 100% of shares. The current president of the company, Dr. Ole Dammann, will remain in KFGN in his current position.
Pratia grows digitally
The acquisition of KFGN is Pratia’s fourth investment this year and the second outside Poland. In February Pratia took over Examen, one of the largest clinical trials centers in western Poland. We have written more about it here. In April, Pratia opened a ward in Ukraine, where it currently (as Pratia Ukraine) operates in six multi-specialist hospitals. It also conducts adaptation works of its own specialist-oncological centre.
In total, Pratia currently operates through over 20 clinical research centres in three countries. The main element of process integration will be a digital platform for managing and conducting clinical research – hyggio. Pratia’s investment in the hyggio platform was finalised in March 2020 as part of the establishment of Clinscience Technologies. Neuca Group, owner of Pratia, operates in several areas of the healthcare market. It conducts wholesale of pharmaceuticals, produces medicines and dietary supplements under own brands (Synoptis Pharma), and manages a network of several dozen clinics under the Swiat Zdrowia brand.